Pages that link to "Q44012109"
Jump to navigation
Jump to search
The following pages link to Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer (Q44012109):
Displaying 50 items.
- Novel and selective imidazole-containing biphenyl inhibitors of protein farnesyltransferase (Q27640801) (← links)
- Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor (Q33201555) (← links)
- Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours (Q33369069) (← links)
- Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study (Q33371141) (← links)
- Exposure-toxicity relationships for tipifarnib in cancer patients (Q33374647) (← links)
- A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study (Q33376981) (← links)
- New insights into the molecular pathogenesis of colorectal cancer (Q33640592) (← links)
- Targeted therapies for pancreatic cancer (Q33899923) (← links)
- Lipid posttranslational modifications. Farnesyl transferase inhibitors (Q34651253) (← links)
- Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo. (Q35012724) (← links)
- Molecular targets in acute myelogenous leukemia (Q35029566) (← links)
- Preclinical and clinical evaluation of farnesyltransferase inhibitors (Q35065182) (← links)
- Advances in Molecular Therapies in Patients with Brain Tumors (Q35113656) (← links)
- Farnesyl transferase inhibitors in clinical development (Q35143993) (← links)
- An overview of farnesyltransferase inhibitors and their role in lung cancer therapy (Q35179421) (← links)
- Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia (Q35186888) (← links)
- A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia (Q35190641) (← links)
- New targeted therapies in gastrointestinal cancers (Q35206799) (← links)
- Farnesyltransferase Inhibitors and Their Role in the Treatment of Multiple Myeloma (Q35569466) (← links)
- Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways (Q35572443) (← links)
- Is There a Standard Chemotherapeutic Regimen for Hormone-Refractory Prostate Cancer? Present and Future Approaches in the Management of the Disease (Q35579300) (← links)
- New molecular targeted therapies for advanced non-small-cell lung cancer (Q35667806) (← links)
- Novel treatments in non-small cell lung cancer (Q35684127) (← links)
- Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: A report from the Children's Oncology Group (Q35729250) (← links)
- Novel targeted agents in the treatment of lung cancer (Q35790783) (← links)
- Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients (Q35827635) (← links)
- Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice (Q35829431) (← links)
- Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies (Q35872060) (← links)
- Molecularly targeted therapy for pediatric brain tumors (Q36272981) (← links)
- Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104) (Q36526919) (← links)
- Emerging drugs to replace current leaders in first-line therapy for breast cancer (Q36580598) (← links)
- Clinical activity of tipifarnib in hematologic malignancies (Q36736368) (← links)
- Inhibition of farnesyltransferase: a rational approach to treat cancer? (Q36828655) (← links)
- Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia (Q37183513) (← links)
- Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies (Q37441525) (← links)
- Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib (Q37733593) (← links)
- Targeting MAPK pathway in melanoma therapy (Q38098888) (← links)
- Mutation-promoting molecular networks of uncontrolled inflammation (Q38666215) (← links)
- A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma (Q40432628) (← links)
- The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease (Q40652703) (← links)
- Tipifarnib in the treatment of acute myeloid leukemia (Q42217527) (← links)
- Evaluation of the bioequivalence of tablets and capsules containing the novel anticancer agent R115777 (Zarnestra) in patients with advanced solid tumors (Q43983488) (← links)
- Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients (Q44879826) (← links)
- Targeted therapies in thoracic oncology (Q45006400) (← links)
- Prediction of Apparent Oral Clearance of Small-Molecule Inhibitors in Pediatric Patients (Q47605042) (← links)
- Targeting the RAS signalling pathway in cancer (Q53237008) (← links)
- Induction and postremission therapy: new agents (Q73149868) (← links)
- Highlights from: 38th annual meeting of the American Society of Clinical Oncology (Q78578004) (← links)
- Molecularly Targeted Chemoprevention of Lung Cancer (Q79278112) (← links)
- Farnesyltransferase inhibitors (Q80510506) (← links)